加载中
NASDAQHealthcareMedical - Pharmaceuticals
最新数据
US$26.765
−US$0.905 · -3.27%
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
常规交易时段
US$26.7888
−US$0.8812 · -3.18%
盘中时间采用ET。市场数据可能有所延迟。
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
日内区间
当前US$26.7888
52周区间
当前US$26.7888
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
87
深度低估
情绪
47
多空交织
风险
37
中等风险
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
日内区间
当前US$26.7888
52周区间
当前US$26.7888
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.58亿 USD | 1399.6万 USD | 1748.8万 USD | 1593.5万 USD | 1285.3万 USD |
| 销货成本 | 1324.2万 USD | 587.9万 USD | 288.8万 USD | 285.9万 USD | 302.3万 USD |
| 毛利 | 1.45亿 USD | 811.7万 USD | 1460万 USD | 1307.6万 USD | 983万 USD |
| 研究与开发 | 3927.6万 USD | 4784.2万 USD | 4324.2万 USD | 1943.5万 USD | 2051.7万 USD |
| 销售、一般及管理费用 | 1.57亿 USD | 8156.9万 USD | 4474.2万 USD | 3241.1万 USD | 2311万 USD |
| 营业费用 | 1.96亿 USD | 1.29亿 USD | 8798.4万 USD | 5184.6万 USD | 4362.7万 USD |
| 利息收入 | 662.4万 USD | 765.4万 USD | 346.6万 USD | 109万 USD | 3.3万 USD |
| 利息支出 | 2417.2万 USD | 1248.6万 USD | 627.3万 USD | 233.8万 USD | 76.2万 USD |
| 折旧和摊销 | 152.8万 USD | 219.7万 USD | 217.8万 USD | 364.7万 USD | 561.2万 USD |
| 营业利润 | −5137.6万 USD | −1.21亿 USD | −7338.4万 USD | −3877万 USD | −3379.7万 USD |
| 净利润 | −6892.4万 USD | −1.3亿 USD | −7850.2万 USD | −4101.5万 USD | −3457.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.54亿0.01%2.3万亿 USD0.03%US$381.5-0.02%
Vanguard Extended Market ETFVXF5564.44万0.06%954亿 USD0.05%US$232.58-0.40%
iShares Russell 2000 ETFIWM5003.74万0.07%787.4亿 USD0.19%US$276.98-0.33%
Vanguard Russell 2000 ETFVTWO2765.28万0.15%180亿 USD0.06%US$111.87-0.36%
Invesco S&P SmallCap Momentum ETFXSMO2416.31万0.85%28.69亿 USD0.35%US$80.99-0.39%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1880.96万0.12%157.12亿 USD0.03%US$53.475+0.10%
iShares Russell 2000 Growth ETFIWO1803.74万0.13%139.17亿 USD0.24%US$351.51-0.62%
Vanguard S&P Small-Cap 600 ETFVIOO1723.56万0.27%64亿 USD0.07%US$127.99+0.12%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOInvesco S&P SmallCap Momentum ETFXSMOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOVanguard S&P Small-Cap 600 ETFVIOOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
